Journal article · 2026 · Open access

Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial

Xavier Puéchal, G. Pugnet, Benjamin Thoreau, Claire DE MOREUIL, S. Jouneau, Thomas Quéméneur, Gabriel Baron, P. Smets, Antoine Néel, Thomas Le Gallou, Nicolas Noël, Y. Uzunhan and 57 more

JAMA · Published 22 October 2026 · DOI 10.1001/jama.2026.15278

Open full textView at the publisherCite this paper

In brief

“Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial” is a 2026 journal article by Xavier Puéchal and 68 co-authors, published in JAMA. OpenAlex counts 2 citations as of 17 November 2026, which puts it in the top 6% of works published in 2026 by citations. It is open access: the full text is free to read at PubMed Central.

Citations
2
Most cited in
2026 (2)
Field-weighted impact
6.12
References
26
Authors
69

Abstract

Importance: For patients with eosinophilic granulomatosis with polyangiitis (EGPA), guidelines recommend considering maintenance therapy after achieving remission. Data comparing maintenance therapeutic options are limited. Objective: To compare the effects of rituximab and azathioprine maintenance therapies on remission duration for patients with EGPA who recently achieved remission of vasculitis after standard therapy, including prednisone tapering or withdrawal. Design, Setting, and Participants: From March 7, 2018, to June 2, 2022, this double-blind, double-dummy, investigator-initiated, superiority, randomized clinical trial enrolled 98 participants with EGPA from 36 hospitals in France. Inclusion eligibility required a new EGPA diagnosis or relapsing EGPA within 30 to 360 days of achieving vasculitis remission (Birmingham Vasculitis Activity Score of 0 [range, 0-63, with higher scores indicating more severe disease activity]) after a standard induction regimen. Data were analyzed from April 1, 2025, to September 17, 2025. Additional analyses ended June 22, 2026. Interventions: Participants were randomized to receive a predefined standardized tapering of oral prednisone and either 500 mg of intravenous rituximab every 6 months for 18 months and daily oral azathioprine placebo for 24 months (n = 49) or rituximab placebo every 6 months for 18 months and daily oral azathioprine for 24 months (n = 49). Main Outcomes and Measures: The primary efficacy end point was the duration of total remission during the 28-month study period while taking 7.5 mg/d or less of prednisone. The 14 secondary end points included proportion of participants remaining in remission, rate of vasculitis relapse, and rate of asthma or rhinosinusitis exacerbations. Results: All 98 randomized participants (mean age, 59.0 years [SD, 14.4]; 50 women [51%]) received at least 1 dose of the trial regimen and 92 (94%) completed the trial. The mean time in remission with prednisone at 7.5 mg/d or less was 91.1 weeks (95% CI, 80.9-101.2) vs 96.0 weeks (95% CI, 85.6-106.5) in the rituximab and azathioprine groups, respectively (P = .38). The proportion of participants who remained in remission during the 28-month study period with prednisone at 7.5 mg/d or less was 17 of 49 (34.7%) vs 11 of 49 (22.4%; relative risk, 1.51; 95% CI, 0.83-2.73; P = .18) in the rituximab and azathioprine groups, respectively. The proportion of participants with at least 1 vasculitis relapse was 7 (14.3%) vs 9 (18.4%) in the rituximab vs azathioprine groups, respectively, and for those with at least 1 clinically significant asthma exacerbation, rhinosinusitis exacerbation, or both, it was 16 (32.7%) vs 19 (38.8%). One participant in the azathioprine group died of SARS-CoV-2 infection before vaccine development. Rituximab recipients experienced…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Puéchal, X., Pugnet, G., Thoreau, B., DE MOREUIL, C., Jouneau, S., Quéméneur, T., Baron, G., Smets, P., Néel, A., Le Gallou, T., Noël, N., Uzunhan, Y., Comarmond-Ortoli, C., Urbanski, G., Benhamou, Y., BEREZNE, A., Mekinian, A., Hamidou, M. A., Campagne, J., . . . Boffa, J. (2026). Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.15278

MLA 9

Puéchal, Xavier, et al. “Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial.” JAMA, 2026. https://doi.org/10.1001/jama.2026.15278.

Chicago

Puéchal, Xavier, G. Pugnet, Benjamin Thoreau, Claire DE MOREUIL, S. Jouneau, Thomas Quéméneur, Gabriel Baron, et al. 2026. “Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial.” JAMA. https://doi.org/10.1001/jama.2026.15278.

Harvard

Puéchal, X. et al. (2026) ‘Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial’, JAMA. doi:10.1001/jama.2026.15278.

IEEE

X. Puéchal et al., “Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial,” JAMA, 2026, doi: 10.1001/jama.2026.15278.

BibTeX

@article{puechal2026rituximab,
  title     = {{Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial}},
  author    = {Puéchal, Xavier and Pugnet, G. and Thoreau, Benjamin and DE MOREUIL, Claire and Jouneau, S. and Quéméneur, Thomas and Baron, Gabriel and Smets, P. and Néel, Antoine and Le Gallou, Thomas and Noël, Nicolas and Uzunhan, Y. and Comarmond-Ortoli, Chloé and Urbanski, G. and Benhamou, Y. and BEREZNE, ALICE and Mekinian, Arsène and Hamidou, Mohamed Amine and Campagne, Julien and Abisror, Noémie and Cohen, Pascal and Guillevin, Loïc and Ravaud, Philippe and Terrier, Benjamin and French Vasculitis Study Group and DIOT, Elisabeth and London, Jonathan and Legendre, Paul and Dossier, Antoine and SCHLEINITZ, Nicolas and others},
  journal   = {JAMA},
  year      = {2026},
  doi       = {10.1001/jama.2026.15278},
  url       = {https://doi.org/10.1001/jama.2026.15278}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions

  • eosinophilic granulomatosis with polyangiitis
  • maintenance therapy
  • rituximab
  • azathioprine
  • vasculitis remission
  • prednisone tapering
  • relapse
  • asthma exacerbations

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Puéchal, X., Pugnet, G., Thoreau, B., DE MOREUIL, C., Jouneau, S., Quéméneur, T., Baron, G., Smets, P., Néel, A., Le Gallou, T., Noël, N., Uzunhan, Y., Comarmond-Ortoli, C., Urbanski, G., Benhamou, Y., BEREZNE, A., Mekinian, A., Hamidou, M. A., Campagne, J., . . . Boffa, J. (2026). Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.15278

How many times has this paper been cited?

2 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PubMed Central: sign in and open the full text from this page.

Who wrote this paper?

Xavier Puéchal, G. Pugnet, Benjamin Thoreau, Claire DE MOREUIL, S. Jouneau, Thomas Quéméneur, Gabriel Baron, P. Smets, Antoine Néel, Thomas Le Gallou, Nicolas Noël, Y. Uzunhan and 57 more.

What is the DOI of this paper?

10.1001/jama.2026.15278, permanently at https://doi.org/10.1001/jama.2026.15278. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.